Three dimensional in vitro culture systems in anticancer drug discovery targeted on cancer stem cells.
3D cell cultures
Cancer stem cells (CSC)
anticancer drug discovery
cancer organoids
hanging drop (HD)
lab-on-a-chip
matrix
micro fluidics
solid-phase spheroids
ultra-low attachment plates (ULA)
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
06
2021
accepted:
28
07
2021
entrez:
12
11
2021
pubmed:
13
11
2021
medline:
13
11
2021
Statut:
epublish
Résumé
Worldwide, tumors are one of the most common causes of death. Every year 3.7 million new cases occur in Europe and more than 1.9 million patients die (WHO data). Most of the fields of research are focused on developing new therapeutic strategies that will be effective in eliminating the tumor, preventing its remission, and avoiding or reducing the side effects of therapy. In the past, generally classical 2D cell cultures or immunodeficient animal models had been used to cultivate and test drugs on human cancer cell lines. Nowadays, there are increasing interests in three-dimensional (3D) cell cultures, a method with significant differences from flat cultured cells, both considering gene expressions and cell-cell interactions. Various evidence suggests that high tumorigenic properties might be dependent on the occurrence of a small cell population, pointed out to be responsible for metastasis and recurrence. This population is called cancer stem cells (CSCs), hinted to have a lot of similarities with normal stem cells. CSCs are the main reason for chemotherapy failure as well as multi-drug resistance (MDR). CSCs can also interact through the cytokine network, with other cells like the macrophages of the inflammatory system. The big advantage of a 3D culture is the possibility to isolate and investigate the CSCs population surrounded by its environment. This article aims to sum up known 3D cell cultures, especially in the field of CSCs research due to the importance of the tumor's environment on stem cell's markers expression and their development.
Types de publication
Journal Article
Langues
eng
Pagination
4931-4946Informations de copyright
AJCR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
J Immunother Cancer. 2019 Jul 19;7(1):190
pubmed: 31324218
Lab Chip. 2007 Mar;7(3):302-9
pubmed: 17330160
Methods Mol Biol. 2018;1692:61-75
pubmed: 28986887
Biochem J. 2018 May 9;475(9):1611-1634
pubmed: 29743249
Br J Cancer. 2020 Mar;122(6):735-744
pubmed: 31894140
Front Oncol. 2019 Oct 24;9:1104
pubmed: 31709180
Oncotarget. 2017 Jun 13;8(57):96852-96864
pubmed: 29228576
BMC Biol. 2012 Mar 22;10:29
pubmed: 22439642
Biotechniques. 2018 Oct;65(4):197-203
pubmed: 30284938
Clin Transl Oncol. 2020 Jul;22(7):1155-1165
pubmed: 31748959
Cell Death Dis. 2013 Oct 17;4:e857
pubmed: 24136221
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030
Eur Spine J. 2008 Dec;17 Suppl 4:467-79
pubmed: 19005702
Small. 2020 Mar;16(9):e1901001
pubmed: 30998296
Biomaterials. 2003 Nov;24(24):4337-51
pubmed: 12922147
Lab Chip. 2010 Jul 7;10(13):1671-7
pubmed: 20414488
BioDrugs. 2018 Feb;32(1):53-68
pubmed: 29383499
Asian Pac J Cancer Prev. 2020 Mar 01;21(3):611-620
pubmed: 32212785
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4567-4574
pubmed: 30787188
Methods Mol Biol. 2018;1683:355-369
pubmed: 29082502
World J Stem Cells. 2019 Jul 26;11(7):398-420
pubmed: 31396368
Curr Med Sci. 2019 Jun;39(3):403-409
pubmed: 31209810
Int J Mol Sci. 2018 Jan 18;19(1):
pubmed: 29346265
SLAS Discov. 2017 Jun;22(5):456-472
pubmed: 28520521
Front Mol Biosci. 2020 Mar 06;7:33
pubmed: 32211418
Oncotarget. 2018 Apr 20;9(30):21211-21223
pubmed: 29765532
BMC Cancer. 2019 Aug 1;19(1):760
pubmed: 31370822
Oncol Lett. 2017 Dec;14(6):6999-7010
pubmed: 29344128
Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110
pubmed: 25510809
Stem Cell Rev Rep. 2020 Apr;16(2):397-412
pubmed: 31965409
Life Sci. 2019 Oct 1;234:116781
pubmed: 31430455
Angiogenesis. 2004;7(2):97-103
pubmed: 15516830
Cancer Cell Int. 2019 Jan 14;19:16
pubmed: 30651721
Am J Pathol. 2011 Jul;179(1):487-501
pubmed: 21703426
BMC Biotechnol. 2007 Dec 10;7:88
pubmed: 18070345
Cancer Sci. 2017 Dec;108(12):2383-2392
pubmed: 29024204
Redox Biol. 2019 Jul;25:101056
pubmed: 30509603
Mol Med Rep. 2020 Nov;22(5):3747-3758
pubmed: 32901865
Oncotarget. 2016 Mar 29;7(13):16948-61
pubmed: 26918944
Clin Transl Med. 2021 Feb;11(2):e308
pubmed: 33635003
PLoS One. 2020 Mar 26;15(3):e0230230
pubmed: 32214328
Front Pharmacol. 2020 Mar 06;11:198
pubmed: 32210805
Front Pharmacol. 2020 Jun 17;11:904
pubmed: 32625096
Proc Biol Sci. 2002 Jun 22;269(1497):1211-5
pubmed: 12065036
Proteome Sci. 2014 Jul 11;12:39
pubmed: 25075203
J Hematol Oncol. 2018 Sep 15;11(1):116
pubmed: 30219074
Breast Cancer Res. 2010;12(6):R94
pubmed: 21067584
Curr Opin Biotechnol. 2001 Feb;12(1):75-81
pubmed: 11167077
Cell Res. 2012 Mar;22(3):457-72
pubmed: 22357481
Gels. 2018 Aug 02;4(3):
pubmed: 30674841
Cell Rep. 2018 Feb 6;22(6):1600-1614
pubmed: 29425513
Cells. 2020 Aug 13;9(8):
pubmed: 32823711
Acta Biomater. 2016 Jun;37:83-92
pubmed: 27109764
Biomaterials. 2008 Aug;29(22):3237-44
pubmed: 18455231
Front Physiol. 2017 Aug 22;8:605
pubmed: 28878686
Cancer Sci. 2017 Mar;108(3):283-289
pubmed: 28064442
J Mater Sci Mater Med. 2005 Jun;16(6):515-9
pubmed: 15928866
Ultrason Sonochem. 2019 Nov;58:104615
pubmed: 31450294
Pharmacol Ther. 2016 Jul;163:94-108
pubmed: 27063403
Lab Chip. 2013 Oct 21;13(20):4124-33
pubmed: 23969512
Semin Cancer Biol. 2018 Dec;53:258-264
pubmed: 29966678
J Exp Clin Cancer Res. 2018 Jan 5;37(1):2
pubmed: 29304852
Nature. 2001 Jun 21;411(6840):924-7
pubmed: 11418851